Subscribe to our News Updates & Alerts
ASX AGN:
A$
Home
About
Company Overview
Our Mission
Board & Management
Clinical Advisory Committee
Partnerships
Investors
Share Information
Announcements & Reports
ASX Announcements
Corporate Directory
Corporate Governance
Technology
The Science
Development
Publications
Media
News & Media
Contact
ASX Announcements
2022
2021
19 May 2022
Successful Completion of Final Pre-Clinical PK Study
05 May 2022
GLP Safety Studies Successfully Completed
29 Apr 2022
Quarterly Activities/Appendix 4C Cash Flow Report
26 Apr 2022
Maximum Tolerated Dose Successfully Established in Studies
04 Apr 2022
Initial Director's Interest Notice
04 Apr 2022
Argenica Appoints CEO Dr Liz Dallimore Managing Director
30 Mar 2022
Positive Preclincal Data on Efficacy in New Indication
21 Mar 2022
Peer Reviewed Paper Published on Preclinical Study
16 Mar 2022
Investor Presentation
28 Feb 2022
Change of Director's Interest Notice
24 Feb 2022
Successful Completion of Final GLP Genotoxicity Studies
22 Feb 2022
Half Yearly Report and Accounts
27 Jan 2022
Quarterly Activities/Appendix 4C Cash Flow Report
24 Jan 2022
Preliminary Pre-Clinical Tox Studies Successfully Completed
13 Jan 2022
Argenica Appoints Head of Clinical Development
13 Jan 2022
Notification regarding unquoted securities - AGN
31 Dec 2021
Application for quotation of securities - AGN
17 Dec 2021
Application for quotation of securities - AGN
10 Dec 2021
Release of Restricted Securities from Escrow
09 Dec 2021
Argenica to be Granted Patent Protection in the US
17 Nov 2021
Results of Annual General Meeting
17 Nov 2021
AGM Presentation
03 Nov 2021
Positive Preclinical Data for ARG-007 Neuroprotection in HIE
28 Oct 2021
Quarterly Activities/Appendix 4C Cash Flow Report
27 Oct 2021
Investor Presentation
18 Oct 2021
Phase 1 Clinical Trial Overview & Roadmap
15 Oct 2021
Notice of Annual General Meeting/Proxy Form
14 Oct 2021
Application for quotation of securities - AGN
04 Oct 2021
Release of Restricted Securities from Escrow
30 Sep 2021
Argenica Partners With Linear For Phase 1 Clinical Trial
21 Sep 2021
Date of AGM & Closing Date for Director Nominations
14 Sep 2021
Argenica Achieves Manufacturing Milestones
27 Aug 2021
Appendix 4G & Corporate Governance Statement
27 Aug 2021
Appendix 4E & Annual Report 30 June 2021
11 Aug 2021
Appendix 3G
05 Aug 2021
Proposed issue of securities - AGN
05 Aug 2021
Issue of Options
29 Jul 2021
Quarterly Activities/Appendix 4C Cash Flow Report
21 Jul 2021
Grant Secured to Advance Pre-Clinical Studies Of ARG-007
13 Jul 2021
Study Additional Information
12 Jul 2021
Study Shows ARG-007 Does Not Degrade
01 Jul 2021
Argenica Completes Pilot Pre-Clinical Pharmacokinetics Study
30 Jun 2021
Change of Registered Office
16 Jun 2021
Investor Presentation
11 Jun 2021
Argenica Commences Trading on ASX
09 Jun 2021
Becoming a substantial holder
09 Jun 2021
Becoming a substantial holder
09 Jun 2021
Initial Director's Interest Notice x4
09 Jun 2021
Confirmation Statements
09 Jun 2021
Top 20 Holders
09 Jun 2021
Distribution Schedule
09 Jun 2021
Securities Trading Policy
09 Jun 2021
Corporate Governance Statement
09 Jun 2021
Employee Securities Incentive Plan
09 Jun 2021
Interim Report for the period ended 31 December 2020
09 Jun 2021
Annual Report for period from incorporation to 30 June 2020
09 Jun 2021
Constitution
09 Jun 2021
Prospectus
09 Jun 2021
Appendix 1A & Information Form and Checklist
09 Jun 2021
ASX Notice - Admission to Official List
ASX Announcements
Subscribe to our mailing list to stay up to date with Argenica Therapeutics
First Name
*
Last Name
*
Email
*
Home
About
Company Overview
Our Mission
Board & Management
Clinical Advisory Committee
Partnerships
Investors
Share Information
Announcements & Reports
ASX Announcements
Corporate Directory
Corporate Governance
Technology
The Science
Development
Publications
Media
News & Media
Contact
Privacy Policy
Terms & Conditions